Search Orphan Drug Designations and Approvals
-
| Generic Name: | recombinant bispecific human IgG4 antibody which functionally mimics the procoagulant properties of activated FVIII |
|---|---|
| Date Designated: | 05/10/2021 |
| Orphan Designation: | Treatment of Hemophilia A |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Novo Nordisk, Inc. 800 Scudders Mill Rd. Plainsboro, New Jersey 08536 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







